Comparative Pharmacology
Head-to-head clinical analysis: KARIVA versus NORDETTE 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KARIVA versus NORDETTE 21.
KARIVA vs NORDETTE-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to prevent sperm penetration, and alters endometrial lining to reduce implantation likelihood.
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours; in renal impairment (CrCl <30 mL/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Ethinylestradiol: 13 ± 7 hours (terminal), clinically relevant for once-daily dosing; Levonorgestrel: 24 ± 6 hours (terminal), supporting steady-state after ~5 days
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Renal: ~50% (as glucuronide and sulfate conjugates); Fecal: ~40% (enterohepatic recirculation); Biliary: <10%
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive